With the deepening of the research on the mechanism of RCC, drugs targeting the pathogenesis of RCC, such as VEGF inhibitors or Mechanistic Target of Rapamycin Complex 1 (mTORC1) inhibitors, have also been continuously developed and applied. This evidence concerns the gene VEGFA and renal cell carcinoma.